Tumor-infiltrating lymphocytes (TILs) from patients with glioma

OncoImmunology

Volumn 6, Issue 2, 2017, Pages

  Liu, Zhenjiang ^a   Meng, Qingda ^a   Bartek, Jiri ^a,b,c   Poiret, Thomas ^a   Persson, Oscar ^b   Rane, Lalit ^a   Rangelova, Elena ^b   Illies, Christopher ^b   Peredo, Inti Harvey ^a,b   Luo, Xiaohua ^a   Rao, Martin Vijayakumar ^a   Robertson, Rebecca Axelsson ^a   Dodoo, Ernest ^a,b   Maeurer, Markus ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c University of Copenhagen   (Denmark)

Author keywords

Brain tumor; cellular therapy; cytokines; glioma; TIL

Indexed keywords

COMPLEMENT COMPONENT C1Q; GAMMA INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN;

ANTIGEN EXPRESSION; ARTICLE; CD3+ CD4- CD8- T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD4- CD8- T LYMPHOCYTE; CD45RA- CCR7+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CENTRAL MEMORY; CHROMIUM RELEASE ASSAY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GLIOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; POLYMERASE CHAIN REACTION; STAINING; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE;

EID: 85011818248     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2016.1252894     Document Type: Article

References (49)

1. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002; 298:850-4; PMID:12242449; http://dx.doi.org/10.1126/science.1076514
2. Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, Citrin DE, Restifo NP, Robbins PF, Wunderlich JR, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res:Off J Am Assoc Cancer Res 2011; 17:4550-7; PMID:21498393; http://dx.doi.org/10.1158/1078-0432.CCR-11-0116
3. Robbins PF, Lu YC, El-Gamil M, Li YF, Gross C, Gartner J, Lin JC, Teer JK, Cliften P, Tycksen E, et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med 2013; 19:747-52; PMID:23644516; http://dx.doi.org/10.1038/nm.3161
4. Lu YC, Yao X, Crystal JS, Li YF, El-Gamil M, Gross C, Davis L, Dudley ME, Yang JC, Samuels Y, et al. Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions. Clin Cancer Res:Off J Am Assoc Cancer Res 2014; 20:3401-10; PMID:24987109; http://dx.doi.org/10.1158/1078-0432.CCR-14-0433
5. Tran E, Turcotte S, Gros A, Robbins PF, Lu YC, Dudley ME, Wunderlich JR, Somerville RP, Hogan K, Hinrichs CS, et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 2014; 344:641-5; PMID:24812403; http://dx.doi.org/10.1126/science.1251102
6. Colombo F, Barzon L, Franchin E, Pacenti M, Pinna V, Danieli D, Zanusso M, Palu G. Combined HSV-TK/IL-2 gene therapy in patients with recurrent glioblastoma multiforme:biological and clinical results. Cancer Gene Ther 2005; 12:835-48; PMID:15891772; http://dx.doi.org/10.1038/sj.cgt.7700851
7. Kruse CA, Cepeda L, Owens B, Johnson SD, Stears J, Lillehei KO. Treatment of recurrent glioma with intracavitary alloreactive cytotoxic T lymphocytes and interleukin-2. Cancer Immunol, Immunother:CII 1997; 45:77-87; PMID:9390198; http://dx.doi.org/10.1007/s002620050405
8. Hayes RL, Arbit E, Odaimi M, Pannullo S, Scheff R, Kravchinskiy D, Zaroulis C. Adoptive cellular immunotherapy for the treatment of malignant gliomas. Crit Rev Oncol/Hematol 2001; 39:31-42; PMID:11418300; http://dx.doi.org/10.1016/S1040-8428(01)00122-6
9. Dillman RO, Duma CM, Ellis RA, Cornforth AN, Schiltz PM, Sharp SL, DePriest MC. Intralesional lymphokine-activated killer cells as adjuvant therapy for primary glioblastoma. J Immunother 2009; 32:914-9; PMID:19816190; http://dx.doi.org/10.1097/CJI.0b013e3181b2910f
10. Jacobs SK, Wilson DJ, Kornblith PL, Grimm EA. Interleukin-2 or autologous lymphokine-activated killer cell treatment of malignant glioma:phase I trial. Cancer Res 1986; 46:2101-4; PMID:3512079
11. Dillman RO, Duma CM, Schiltz PM, DePriest C, Ellis RA, Okamoto K, Beutel LD, De Leon C, Chico S. Intracavitary placement of autologous lymphokine-activated killer (LAK) cells after resection of recurrent glioblastoma. J Immunother 2004; 27:398-404; PMID:15314549; http://dx.doi.org/10.1097/00002371-200409000-00009
12. Sankhla SK, Nadkarni JS, Bhagwati SN. Adoptive immunotherapy using lymphokine-activated killer (LAK) cells and interleukin-2 for recurrent malignant primary brain tumors. J Neuro-oncol 1996; 27:133-40; PMID:8699235; http://dx.doi.org/10.1007/BF00177476
13. Hayes RL, Koslow M, Hiesiger EM, Hymes KB, Hochster HS, Moore EJ, Pierz DM, Chen DK, Budzilovich GN, Ransohoff J. Improved long term survival after intracavitary interleukin-2 and lymphokine-activated killer cells for adults with recurrent malignant glioma. Cancer 1995; 76:840-52; PMID:8625188; http://dx.doi.org/10.1002/1097-0142(19950901)76:5%3c840::AID-CNCR2820760519%3e3.0.CO;2-R
14. Boiardi A, Silvani A, Ruffini PA, Rivoltini L, Parmiani G, Broggi G, Salmaggi A. Loco-regional immunotherapy with recombinant interleukin-2 and adherent lymphokine-activated killer cells (A-LAK) in recurrent glioblastoma patients. Cancer Immunol, Immunother:CII 1994; 39:193-7; PMID:7923250; http://dx.doi.org/10.1007/BF01533386
15. Blancher A, Roubinet F, Grancher AS, Tremoulet M, Bonate A, Delisle MB, Calot JP, Pourreau C, Franks C, Ducos J, et al. Local immunotherapy of recurrent glioblastoma multiforme by intracerebral perfusion of interleukin-2 and LAK cells. Eur Cytokine Network 1993; 4:331-41; PMID:8117934
16. Jeffes EW, 3rd, Beamer YB, Jacques S, Silberman RS, Vayuvegula B, Gupta S, Coss JS, Yamamoto RS, Granger GA. Therapy of recurrent high grade gliomas with surgery, and autologous mitogen activated IL-2 stimulated killer (MAK) lymphocytes:I. Enhancement of MAK lytic activity and cytokine production by PHA and clinical use of PHA. J Neuro-Oncol 1993; 15:141-55; PMID:8509819; http://dx.doi.org/10.1007/BF01053935
17. Barba D, Saris SC, Holder C, Rosenberg SA, Oldfield EH. Intratumoral LAK cell and interleukin-2 therapy of human gliomas. J Neurosurg 1989; 70:175-82; PMID:2643685; http://dx.doi.org/10.3171/jns.1989.70.2.0175
18. Merchant RE, Grant AJ, Merchant LH, Young HF. Adoptive immunotherapy for recurrent glioblastoma multiforme using lymphokine activated killer cells and recombinant interleukin-2. Cancer 1988; 62:665-71; PMID:2840186; http://dx.doi.org/10.1002/1097-0142(19880815)62:4%3c665::AID-CNCR2820620403%3e3.0.CO;2-O
19. Quattrocchi KB, Miller CH, Cush S, Bernard SA, Dull ST, Smith M, Gudeman S, Varia MA. Pilot study of local autologous tumor infiltrating lymphocytes for the treatment of recurrent malignant gliomas. J Neuro-Oncol 1999; 45:141-57; PMID:10778730; http://dx.doi.org/10.1023/A:1006293606710
20. Santegoets SJ, Turksma AW, Suhoski MM, Stam AG, Albelda SM, Hooijberg E, Scheper RJ, van den Eertwegh AJ, Gerritsen WR, Powell DJ, Jr et al. IL-21 promotes the expansion of CD27+ CD28+ tumor infiltrating lymphocytes with high cytotoxic potential and low collateral expansion of regulatory T cells. J Trans Med 2013; 11:37; PMID:23402380; http://dx.doi.org/10.1186/1479-5876-11-37
21. Imataki O, Ansen S, Tanaka M, Butler MO, Berezovskaya A, Milstein MI, Kuzushima K, Nadler LM, Hirano N. IL-21 can supplement suboptimal Lck-independent MAPK activation in a STAT-3-dependent manner in human CD8(+) T cells. J Immunol 2012; 188:1609-19; PMID:22238455; http://dx.doi.org/10.4049/jimmunol.1003446
22. Butler MO, Lee JS, Ansen S, Neuberg D, Hodi FS, Murray AP, Drury L, Berezovskaya A, Mulligan RC, Nadler LM, et al. Long-lived antitumor CD8+ lymphocytes for adoptive therapy generated using an artificial antigen-presenting cell. Clin Cancer Res:Off J Am Assoc Cancer Res 2007; 13:1857-67; PMID:17363542; http://dx.doi.org/10.1158/1078-0432.CCR-06-1905
23. Li Y, Bleakley M, Yee C. IL-21 influences the frequency, phenotype, and affinity of the antigen-specific CD8 T cell response. J Immunol 2005; 175:2261-9; PMID:16081794; http://dx.doi.org/10.4049/jimmunol.175.4.2261
24. Oh S, Perera LP, Burke DS, Waldmann TA, Berzofsky JA. IL-15/IL-15Ralpha-mediated avidity maturation of memory CD8+ T cells. Proc Natl Acad Sci USA 2004; 101:15154-9; PMID:15477598; http://dx.doi.org/10.1073/pnas.0406649101
25. Roussel E, Gingras MC, Grimm EA, Bruner JM, Moser RP. Predominance of a type 2 intratumoural immune response in fresh tumour-infiltrating lymphocytes from human gliomas. Clin Exp Immunol 1996; 105:344-52; PMID:8706344; http://dx.doi.org/10.1046/j.1365-2249.1996.d01-753.x
26. Bodmer S, Strommer K, Frei K, Siepl C, de Tribolet N, Heid I, Fontana A. Immunosuppression and transforming growth factor-beta in glioblastoma. Preferential production of transforming growth factor-beta 2. J Immunol 1989; 143:3222-9; PMID:2809198; http://dx.doi.org/0022-1767/89/14310-3222802.00/0
27. Miescher S, Whiteside TL, de Tribolet N, von Fliedner V. In situ characterization, clonogenic potential, and antitumor cytolytic activity of T lymphocytes infiltrating human brain cancers. J Neurosurg 1988; 68:438-48; PMID:3257792; http://dx.doi.org/10.3171/jns.1988.68.3.0438
28. Liu D, Song L, Wei J, Courtney AN, Gao X, Marinova E, Guo L, Heczey A, Asgharzadeh S, Kim E, et al. IL-15 protects NKT cells from inhibition by tumor-associated macrophages and enhances antimetastatic activity. J Clin Investigat 2012; 122:2221-33; PMID:22565311; http://dx.doi.org/10.1172/JCI59535
29. Klebanoff CA, Finkelstein SE, Surman DR, Lichtman MK, Gattinoni L, Theoret MR, Grewal N, Spiess PJ, Antony PA, Palmer DC, et al. IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. Proc Natl Acad Sci USA 2004; 101:1969-74; PMID:14762166; http://dx.doi.org/10.1073/pnas.0307298101
30. Rosenberg SA, Dudley ME. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol 2009; 21:233-40; PMID:19304471; http://dx.doi.org/10.1016/j.coi.2009.03.002
31. Hunder NN, Wallen H, Cao J, Hendricks DW, Reilly JZ, Rodmyre R, Jungbluth A, Gnjatic S, Thompson JA, Yee C. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. New Engl J Med 2008; 358:2698-703; PMID:18565862; http://dx.doi.org/10.1056/NEJMoa0800251
32. Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, Robbins PF, Huang J, Citrin DE, Leitman SF, et al. Adoptive cell therapy for patients with metastatic melanoma:evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol:Off J Am Soc Clin Oncol 2008; 26:5233-9; PMID:18809613; http://dx.doi.org/10.1200/JCO.2008.16.5449
33. Yee C, Thompson JA, Byrd D, Riddell SR, Roche P, Celis E, Greenberg PD. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma:in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci USA 2002; 99:16168-73; PMID:12427970; http://dx.doi.org/10.1073/pnas.242600099
34. Berger C, Jensen MC, Lansdorp PM, Gough M, Elliott C, Riddell SR. Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. J Clin Investigat 2008; 118:294-305; PMID:18060041; http://dx.doi.org/10.1172/JCI32103
35. Wherry EJ, Teichgraber V, Becker TC, Masopust D, Kaech SM, Antia R, von Andrian UH, Ahmed R. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat Immunol 2003; 4:225-34; PMID:12563257; http://dx.doi.org/10.1038/ni889
36. Chapuis AG, Thompson JA, Margolin KA, Rodmyre R, Lai IP, Dowdy K, Farrar EA, Bhatia S, Sabath DE, Cao J, et al. Transferred melanoma-specific CD8+ T cells persist, mediate tumor regression, and acquire central memory phenotype. Proc Natl Acad Sci USA 2012; 109:4592-7; PMID:22393002; http://dx.doi.org/10.1073/pnas.1113748109
37. Butler MO, Friedlander P, Milstein MI, Mooney MM, Metzler G, Murray AP, Tanaka M, Berezovskaya A, Imataki O, Drury L, et al. Establishment of antitumor memory in humans using in vitro-educated CD8+ T cells. Sci Trans Med 2011; 3:80ra34; PMID:21525398; http://dx.doi.org/10.1126/scitranslmed.3002207
38. Rutledge WC, Kong J, Gao J, Gutman DA, Cooper LA, Appin C, Park Y, Scarpace L, Mikkelsen T, Cohen ML, et al. Tumor-infiltrating lymphocytes in glioblastoma are associated with specific genomic alterations and related to transcriptional class. Clin Cancer Res:Off J Am Assoc Cancer Res 2013; 19:4951-60; PMID:23864165; http://dx.doi.org/10.1158/1078-0432.CCR-13-0551
39. Brennan PJ, Brigl M, Brenner MB. Invariant natural killer T cells:an innate activation scheme linked to diverse effector functions. Na Rev Immunol 2013; 13:101-17; PMID:23334244; http://dx.doi.org/10.1038/nri3369
40. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, Dirks PB. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003; 63:5821-8; PMID:14522905
41. Galli R, Binda E, Orfanelli U, Cipelletti B, Gritti A, De Vitis S, Fiocco R, Foroni C, Dimeco F, Vescovi A. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res 2004; 64:7011-21; PMID:15466194; http://dx.doi.org/10.1158/0008-5472.CAN-04-1364
42. Ernst A, Hofmann S, Ahmadi R, Becker N, Korshunov A, Engel F, Hartmann C, Felsberg J, Sabel M, Peterziel H, et al. Genomic and expression profiling of glioblastoma stem cell-like spheroid cultures identifies novel tumor-relevant genes associated with survival. Clin Cancer Res:Off J Am Assoc Cancer Res 2009; 15:6541-50; PMID:19861460; http://dx.doi.org/10.1158/1078-0432.CCR-09-0695
43. Di Tomaso T, Mazzoleni S, Wang E, Sovena G, Clavenna D, Franzin A, Mortini P, Ferrone S, Doglioni C, Marincola FM, et al. Immunobiological characterization of cancer stem cells isolated from glioblastoma patients. Clin Cancer Res:Off J Am Assoc Cancer Res 2010; 16:800-13; PMID:20103663; http://dx.doi.org/10.1158/1078-0432.CCR-09-2730
44. Erdag G, Schaefer JT, Smolkin ME, Deacon DH, Shea SM, Dengel LT, Patterson JW, Slingluff CL, Jr Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma. Cancer Res 2012; 72:1070-80; PMID:22266112; http://dx.doi.org/10.1158/0008-5472.CAN-11-3218
45. Dudley ME, Rosenberg SA. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer 2003; 3:666-75; PMID:12951585; http://dx.doi.org/10.1038/nrc1167
46. Pages F, Kirilovsky A, Mlecnik B, Asslaber M, Tosolini M, Bindea G, Lagorce C, Wind P, Marliot F, Bruneval P, et al. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol:off Am Soc Clin Oncol 2009; 27:5944-51; PMID:19858404; http://dx.doi.org/10.1200/JCO.2008.19.6147
47. Meng Q, Liu Z, Rangelova E, Poiret T, Ambati A, Rane L, Xie S, Verbeke C, Dodoo E, Del Chiaro M, et al. Expansion of tumor-reactive T cells from patients with pancreatic cancer. J Immunother 2016; 39:81-9; PMID:26849077; http://dx.doi.org/10.1097/CJI.0000000000000111
48. Magalhaes I, Vudattu NK, Jager E, Maeurer MJ. Tumor antigen-specific T-cells are Present in the CD8alphaalpha+ T-cell effector-memory pool. J Immunother 2008; 31:840-8; PMID:18833003; http://dx.doi.org/10.1097/CJI.0b013e31818883a1
49. Ahmed RK, Poiret T, Ambati A, Rane L, Remberger M, Omazic B, Vudattu NK, Winiarski J, Ernberg I, Axelsson-Robertson R, et al. TCR+CD4-CD8- T cells in antigen-specific MHC class I-restricted T-cell responses after allogeneic hematopoietic stem cell transplantation. J Immunother 2014; 37:416-25; PMID:25198529; http://dx.doi.org/10.1097/CJI.0000000000000047